Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study)

Trial Profile

Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms EVADE
  • Most Recent Events

    • 13 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 27 Jan 2016 Planned end date changed from 1 Oct 2017 to 1 Oct 2018, as reported by ClinicalTrials.gov.
    • 27 Jan 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top